Call for Abstracts

In recent years, diagnostic methods using magnification or NBI, and minimally invasive treatment using EMR/ESD; have become well established in gastric cancer. However, we sometime experience trouble cases with difficult diagnosis or serious complications. In this session, we would like to discuss what is pitfall in endoscopic diagnosis and treatment, and how to avoid and deal with them.

In the treatment of Stage IV gastric cancer, different treatments are intermingling and may be selected depending on the site of metastatic organ or the patients' condition , however, there is no clear evidence or guide line. In this session, we would like to discuss the treatment strategies for Stage IV gastric cancer, including surgery, chemotherapy, and immunotherapy.

The prediction of prognosis using clinicopathological factors is important for gasric cancer patients in determining the strategy of treatment, including surgery and drug therapy. However, it has various advantages and disadvantages in accuracy or invasiveness. In this session, we would like to discuss the usefulness and future prospects of novel prognostic predictors.

Surgical treatment for GIST such as LECS is widespread and has been popularized. On the other hand, the efficacy of tyrosine kinase inhibitor has been reported for GIST with metastases and recurrence, nevertheless, the prognosis of advanced gasric GIST is still poor. In this session, we would like to discuss the current status and future prospects of diagnosis and treatment for GIST.